- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01596166
Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department (EDMigraine-4)
Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department
Study Overview
Status
Intervention / Treatment
Detailed Description
Migraine headache is a painful condition of recurrent moderate to severe head pain associated with nausea, vomiting, photophobia, and phonophobia. The condition is highly prevalent and a significant community health problem with considerable impact on the health care system. To alleviate the pain and morbidity associated with a migraine attack, drug therapies are often employed including simple analgesics like ibuprofen and migraine-specific medications like sumatriptan. When these treatments fail or in severe, intractable cases, patients and families may present to the Emergency Department (ED).
Ketorolac in combination with metoclopramide or prochlorperazine was the most common multi-drug combination used in 36% of ED presentations for migraine across Canada in our national practice variation study. The scientific rationale for combining a non-selective non-steroidal anti-inflammatory drug (NSAID) with inhibition of both the cyclooxygenase (COX) 1 and 2 isoenzymes with other migraine therapies is enticing; however, no studies have specifically examined the relative efficacy of the practice. Why would the combination of a non-selective NSAID like ketorolac with other migraine therapies improve treatment outcomes? The benefit of multi-target combinations may be relate to the duration of the migraine and the multiple brain areas involved in sustained pain. It has long been recognized that patients who treat their migraine headaches early at the onset have a better response. The underlying mechanism for this phenomenon has now been identified. The initiation of migraine pain requires activation of the trigeminal (5th cranial nerve) nociceptive (pain) system. Activation of these sensory fibers within the arachnoid membrane on the surface of the brain produces the first and most common painful manifestation of migraine - the pulsatile headache. With each heartbeat, minor dilation of the cerebral blood vessels produces stretch and a painful activation of the trigeminal fibers known as peripheral sensitization. The second phase in the maintenance of a migraine attack over several hours is the sensitization of trigeminal pain pathways leading to higher brain centers known as central sensitization. The efficacy of medications like the triptans is greater early in the course of a migraine attack when there is only peripheral sensitization and before the onset of central sensitization. Non-selective NSAIDs like naproxen sodium and ketorolac may be uniquely effective in the reduction of central sensitization in the animal model of migraine and the reduction of migraine pain in adult patients late in the course of a migraine headache.
The population of patients in the ED is uniquely different from outpatients in that most have developed their migraine headache hours or days before presenting. In our practice variation study, the mean duration of the migraine prior to presenting to the ED was 2 days. Including an NSAID when treating a prolonged migraine in the ED may thus increase the therapeutic window and improve outcomes. While many Canadian ED physicians have adopted the practice of combining ketorolac with other migraine therapies, the gold standard assessment of efficacy and safety in a randomized clinical trial has not been applied.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Canada, T6G 2C8
- Stollery Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A patient is legible to participate in this study if they meet the following criteria:
- Patient is between 6 and 17 years of age inclusive
- Treatment with usual therapy at home or at least one dose of oral ibuprofen or acetaminophen has not provided satisfactory relief
- Intravenous therapy is indicated in the opinion of the treating ED physician
Patient has a history of migraine as defined by the International Classification of Headache Disorders - 2nd edition (Appendix 1) and meets the following criteria:
- During headache, at least 1 of the following: nausea and/or vomiting; two of five symptoms (photophobia, phonophobia, difficulty thinking, lightheadedness, or fatigue). Symptoms may be inferred from patient's behavior.
- Headache has at least 2 of the following characteristics: bifrontal/bitemporal or unilateral location; pulsating/throbbing quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity. Symptoms may be inferred from patient's behavior.
Exclusion Criteria:
A patient is not eligible to participate in the study if any of the following criteria apply:
- Patient has a contraindication to the use of metoclopramide or ketorolac in the opinion of the ED physician
- Patient has a ventriculoperitoneal shunt
- Patient has a fever (temperature > 38.5 oC)
- Patient has meningismus or clinical suspicion of meningitis in the opinion of the ED physician
- Patient has a history of head trauma causing headache in the last 1 week prior to presentation to the ED
- Patient is unable to complete the efficacy assessments (e.g. language barrier)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Metoclopramide, Ketorolac
|
Ketorolac 0.5 mg/kg (max 30 mg) IV
Other Names:
Metoclopramide 0.2 mg/kg (max 10 mg) IV
Other Names:
|
PLACEBO_COMPARATOR: Metoclopramide, Placebo
|
Metoclopramide 0.2 mg/kg (max 10 mg) IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean reduction in pain intensity
Time Frame: 2 hours
|
Measured on Visual Analogue Scale (VAS).
|
2 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain freedom
Time Frame: 2 hours
|
VAS=0
|
2 hours
|
Headache relief - 33
Time Frame: 2 hours
|
Defined as a 33% reduction on the VAS.
|
2 hours
|
Headache relief - 50
Time Frame: 2 hours
|
Defined as a 50% reduction on the VAS
|
2 hours
|
Presence of nausea
Time Frame: 2 hours
|
2 hours
|
|
Presence of vomiting
Time Frame: 2 hours
|
2 hours
|
|
Use of rescue medications
Time Frame: 2 hours
|
Permitted per protocol 60 minutes after start if intravenous infusion.
|
2 hours
|
Sustained pain-free
Time Frame: 25 hours
|
No recurrence of headache within 24 hours if pain was completely eliminated (VAS = 0) prior to discharge.
|
25 hours
|
Sustained headache relief
Time Frame: 24 hours
|
No increase in headache by 33% on the VAS or 50% on the VAS if headache relief was initially achieved.
|
24 hours
|
Minimum clinically significant difference
Time Frame: 2 hours
|
|
2 hours
|
Adverse events
Time Frame: 2 hours
|
All serious and non-serious adverse events including akathisia and dystonia.
|
2 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lawrence P. Richer, MD, MSc, University of Alberta
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Disease Attributes
- Headache Disorders, Primary
- Headache Disorders
- Emergencies
- Migraine Disorders
- Migraine without Aura
- Migraine with Aura
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antiemetics
- Gastrointestinal Agents
- Dopamine Agents
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Ketorolac
- Ketorolac Tromethamine
- Metoclopramide
Other Study ID Numbers
- EDMIGR-004-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Without Aura
-
Corona Doctors Medical Clinics, Inc.UnknownMigraine Disorders | Chronic Migraine Without Aura, Intractable | Migraine With Typical AuraUnited States
-
TheranicaCompletedMigraine Without Aura | Migraine With AuraIsrael
-
California Medical Clinic for HeadacheUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraUnited States
-
Hospital Clínico Universitario de ValladolidUniversity of Valladolid; Complejo Asistencial Universitario de Palencia; Complejo...RecruitingBrain Diseases | Migraine Disorders | Migraine Without Aura | Migraine With AuraSpain
-
Wake Forest University Health SciencesW.G. "Bill" Hefner Salisbury VA Medical CenterNot yet recruitingMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura
-
University Hospital, AkershusNorwegian Foundation for Health and Rehabilitation; Norwegian Chiropractic...CompletedMigraine Without Aura | Migraine With AuraNorway
-
Vastra Gotaland RegionNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...RecruitingMigraine Without Aura | Migraine With AuraChina
-
Assiut UniversityNot yet recruitingMigraine Without Aura | Migraine With Aura
-
Shahid Beheshti University of Medical SciencesCompletedMigraine Without Aura | Migraine With AuraIran, Islamic Republic of
Clinical Trials on Ketorolac Tromethamine
-
Oman Medical Speciality BoardCompletedAcute Renal ColicOman
-
Darnitsa Pharmaceutical CompanyCompleted
-
William Beaumont Army Medical CenterCompletedMusculoskeletal Pain | Analgesia | Adverse EventUnited States
-
Queen's UniversityCompleted
-
Université Catholique de LouvainAnticancer Fund, BelgiumCompletedCurative Breast Cancer Surgery | Inflammatory Positive/Negative Status | Pre Surgical Incision AdministrationBelgium
-
Seattle Children's HospitalUniversity of WashingtonCompletedPostoperative Pain in InfantsUnited States
-
Beth Israel Deaconess Medical CenterSociety for Obstetric Anesthesia and PerinatologyActive, not recruitingPostoperative Pain | Postpartum Hemorrhage | Blood Loss, Postoperative | Analgesia, Obstetrical | Coagulation Defect; Postpartum | Nonsteroidals (NSAIDs)Toxicity | Ketorolac Adverse ReactionUnited States
-
New Mexico Cancer Care AllianceCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerUnited States
-
Egalet LtdCompleted
-
Egalet LtdCompleted